A. D. Beadell Investment Counsel Inc. Sells 750 Shares of Pfizer Inc. (NYSE:PFE)
A. D. Beadell Investment Counsel Inc. Sells 750 Shares of Pfizer Inc. (NYSE:PFE)
A. D. Beadell Investment Counsel Inc. lessened its stake in Pfizer Inc. (NYSE:PFE – Get Rating) by 12.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,338 shares of the biopharmaceutical company's stock after selling 750 shares during the quarter. A. D. Beadell Investment Counsel Inc.'s holdings in Pfizer were worth $279,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
据比德尔投资顾问公司在最近提交给美国证券交易委员会(美国证券交易委员会)的13F文件中称，该公司在第二季度减持了辉瑞的股份12.3%。该基金在本季度出售了750股后，持有5338股这家生物制药公司的股票。截至最近向美国证券交易委员会(Securities and Exchange Commission，美国证券交易委员会)提交的文件，Beadell Investment Counsel Inc.持有的辉瑞股份价值27.9万美元。
A number of other hedge funds also recently bought and sold shares of the company. LMR Partners LLP bought a new stake in Pfizer during the 4th quarter valued at about $8,026,000. Continuum Advisory LLC increased its stake in Pfizer by 4.0% during the 4th quarter. Continuum Advisory LLC now owns 40,651 shares of the biopharmaceutical company's stock valued at $833,000 after purchasing an additional 1,561 shares in the last quarter. Baltimore Washington Financial Advisors Inc. bought a new stake in Pfizer during the 4th quarter valued at about $290,000. Red Door Wealth Management LLC increased its stake in Pfizer by 3.6% during the 4th quarter. Red Door Wealth Management LLC now owns 100,926 shares of the biopharmaceutical company's stock valued at $5,959,000 after purchasing an additional 3,552 shares in the last quarter. Finally, Stonebridge Capital Advisors LLC increased its stake in Pfizer by 5.4% during the 4th quarter. Stonebridge Capital Advisors LLC now owns 24,968 shares of the biopharmaceutical company's stock valued at $1,474,000 after purchasing an additional 1,290 shares in the last quarter. Institutional investors own 67.90% of the company's stock.
其他一些对冲基金最近也买卖了该公司的股票。LMR Partners LLP在第四季度购买了辉瑞的新股份，价值约8,026,000美元。Continum Consulting LLC在第四季度增持了4.0%的辉瑞股份。Continum Consulting LLC现在拥有40,651股这家生物制药公司的股票，价值833,000美元，上个季度又购买了1,561股。巴尔的摩华盛顿金融顾问公司(Baltimore Washington Financial Advisors Inc.)在第四季度新购入辉瑞股份，价值约29万美元。红门财富管理有限责任公司在第四季度增持辉瑞3.6%的股份。Red Door Wealth Management LLC现在持有这家生物制药公司100,926股股票，价值5959,000美元，上个季度又购买了3,552股。最后，Stonebridge Capital Advisors LLC在第四季度增持了辉瑞5.4%的股份。Stonebridge Capital Advisors LLC现在拥有24,968股这家生物制药公司的股票，价值1,474,000美元，上个季度又购买了1,290股。机构投资者持有该公司67.90%的股份。
Pfizer Price Performance
辉瑞的性价比
Shares of NYSE:PFE opened at $44.08 on Friday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.42 and a quick ratio of 1.20. Pfizer Inc. has a 1-year low of $40.94 and a 1-year high of $61.71. The company has a market capitalization of $247.39 billion, a P/E ratio of 8.63, a P/E/G ratio of 0.54 and a beta of 0.70. The firm's 50 day simple moving average is $48.24 and its two-hundred day simple moving average is $50.32.
纽约证交所：PFE的股票周五开盘报44.08美元。该公司的债务权益比为0.39，流动比率为1.42，速动比率为1.20。辉瑞公司股价跌至40.94美元的一年低点和61.71美元的一年高点。该公司市值为2,473.9亿美元，市盈率为8.63，市盈率为0.54，贝塔系数为0.70。该公司的50日简单移动均线为48.24美元，200日简单移动均线为50.32美元。
Pfizer Announces Dividend
辉瑞宣布分红
The company also recently declared a quarterly dividend, which will be paid on Monday, December 5th. Shareholders of record on Friday, November 4th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 3.63%. The ex-dividend date of this dividend is Thursday, November 3rd. Pfizer's dividend payout ratio is currently 31.31%.
该公司最近还宣布了季度股息，将于12月5日(星期一)支付。11月4日(星期五)登记在册的股东将获得每股0.40美元的股息。这意味着1.60美元的年化股息和3.63%的收益率。本次股息除息日期为11月3日(星期四)。辉瑞的派息比率目前为31.31%。
Analyst Ratings Changes
分析师评级发生变化
A number of analysts have recently commented on PFE shares. Barclays set a $50.00 price target on shares of Pfizer in a research note on Thursday, September 1st. Morgan Stanley reduced their price target on shares of Pfizer from $52.00 to $49.00 and set an "equal weight" rating for the company in a research note on Friday, July 8th. Berenberg Bank set a $44.00 price target on shares of Pfizer in a research note on Wednesday, September 14th. The Goldman Sachs Group set a $50.00 price target on shares of Pfizer in a research note on Thursday, September 1st. Finally, UBS Group set a $59.00 price target on shares of Pfizer in a research note on Thursday, September 1st. Nine research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $57.00.
一些分析师最近对PFE的股票发表了评论。巴克莱在9月1日周四的一份研究报告中为辉瑞股票设定了50.00美元的目标价。摩根士丹利在7月8日周五的一份研究报告中将辉瑞股票的目标价从52.00美元下调至49.00美元，并为该公司设定了“同等权重”的评级。贝伦伯格银行在9月14日星期三的一份研究报告中为辉瑞公司的股票设定了44.00美元的目标价。9月1日星期四，高盛在一份研究报告中为辉瑞设定了50美元的目标股价。最后，瑞银集团在9月1日星期四的一份研究报告中为辉瑞股票设定了59.00美元的目标价。9名研究分析师对该股的评级为持有，10名分析师给出了买入评级，一名分析师对该股发出了强烈的买入评级。根据MarketBeat.com的数据，该公司目前的共识评级为“适度买入”，共识目标价为57.00美元。
About Pfizer
关于辉瑞公司
(Get Rating)
(获取评级)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
辉瑞在全球发现、开发、制造、营销、分销和销售生物制药产品。该公司在不同的治疗领域提供药物和疫苗，包括Premarin系列和Eiquis品牌的心血管代谢和妇女健康；Ibrance、Xtandi、Sutent、Inlyta、Retacritt、Lorbrena和Braftovi品牌的生物制品、小分子、免疫疗法和生物仿制药；舒必乐、Medrol、Zavicefta、Zithromax、Vfend、Panzyga和Paxlovid品牌的无菌注射和抗感染药物以及口服新冠肺炎治疗。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- 免费获取StockNews.com关于辉瑞的研究报告
- 华尔街对Datadog的热情会带来巨大的收益吗？
- MarketBeat：回顾一周9/19-9/23
- 为什么特斯拉的股票保持弹性？
- 小盘股的裁员是楼市的晴雨表吗？
- 好市多盈利后价格疲软是买入的好时机吗？
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
接受辉瑞日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对辉瑞及相关公司评级的每日简明摘要。
译文内容由第三方软件翻译。